DIGITAL BIOLOGY
Features
ICON partners with Anthropic to bring Claude into clinical trial operations
The companies plan to add Claude-powered capabilities to ICON's Orbis platform for trial planning, enrolment risk detection and protocol optimization, alongside client access to insights through Claude. ICON will also roll out Claude by role to developers, knowledge workers, and scientific and clinical teams. These are planned capabilities under a multi-year collaboration.
Schrödinger opens early access to Bunsen, its AI co-scientist for molecular discovery
Bunsen plans and executes Schrödinger's physics-based computational workflows. NVIDIA and Google Cloud will provide computing infrastructure for early customers. The tool is intended to give researchers without computational chemistry expertise access to those methods and let computational chemists run concurrent research sessions. Full commercial release is expected by the end of 2026.
Relation expands GSK collaboration to generate data for cellular foundation models
Relation may receive up to $110 million in upfront and success-based milestone payments. The collaboration will use automated experiments to measure how human cells respond over time to genetic and pharmacological interventions. Multi-omics readouts will feed foundation models including Relation's MORGAN, with the aim of supporting future target discovery.
Causaly adds full-text Sage journals to its AI research platform
The partnership lets Causaly's agents analyze articles from more than 400 Sage and Mary Ann Liebert life-sciences journals, including methods, results tables and supporting data. The integration is a separately purchased add-on. Subscribers can follow evidence links to full articles; customers without journal subscriptions can assess relevance within Causaly before purchasing access through Sage.
Elix pairs AI molecular design with Vienna's protein-dynamics research
The joint research agreement connects Elix's molecular generation and chemoinformatics methods with Julien Orts's University of Vienna group, which studies protein dynamics using NMR spectroscopy. The partners aim to design compounds for difficult targets, including intrinsically disordered proteins and proteins involved in epigenetic signaling and cancer. This is a research programme, not a report of validated drug candidates.